As inflammation contributes to the progression of atherosclerosis, TCZ treatment may be beneficial in protecting patients with RA from cardiovascular events, similar to tumor necrosis factor-alpha (TNF-α) blockers. The gene discussed is TNF; the disease is atherosclerosis.